All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Liso-Cel Maintains Longer-Term Responses in Pretreated Relapsed/Refractory CLL/SLL

February 21st 2024

Tatyana Feldman, MD, highlights updated data for liso-cel in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.

FDA Grants Fast Track Status to IMM-1-104 for Pancreatic Cancer

February 21st 2024

IMM-1-104 received FDA fast track designation for use in patients with pancreatic ductal adenocarcinoma who have progressed on 1 line of treatment.

FDA Approves Bi-weekly Teclistamab Dosing for Relapsed/Refractory Multiple Myeloma

February 20th 2024

The FDA has approved a supplemental Biologics License Application for teclistamab-cqyv (Tecvayli) at a reduced dose of 1.5 mg/kg every 2 weeks in patients with relapsed/refractory multiple myeloma who have achieved and maintained a complete response or greater for at least 6 months.

FDA and EMA Accept Regulatory Submissions for Vorasidenib for IDH-Mutant Diffuse Glioma

February 20th 2024

Vorasidenib has been granted regulatory submission acceptance by the FDA and EMA for IDH-mutant diffuse glioma.

International Childhood Cancer Day Shines a Spotlight on Challenges in Pediatric Oncology

February 20th 2024

Burton Eliot Appel, MD, discusses the importance of recognizing Childhood Cancer Day in pediatric patients with cancer.

Unlocking Long-Term Success: Insights From 5-Year Follow-Up of the CAPTIVATE Trial in CLL/SLL

February 20th 2024

Paolo Ghia, MD, PhD, discusses long-term efficacy data for fixed-duration ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia.

Using Cancer’s Strength to Fight Against It

February 20th 2024

New technique made human T cells 100 times more potent at killing cancer cells.

FDA Grants Priority Review to Adagrasib/Cetuximab Combination Therapy in KRAS G12C–Mutant CRC

February 20th 2024

A sNDA for adagrasib plus cetuximab in advanced KRAS G12C–mutated colorectal cancer was granted priority review by the FDA.

FDA Grants Priority Review to Pembrolizumab Plus Chemotherapy in Endometrial Cancer

February 20th 2024

The sBLA for pembrolizumab plus chemotherapy in endometrial cancer has been granted priority review by the FDA.

Lurbinectedin Displays Superior Risk/Benefit Ratio Over Topotecan in SCLC

February 20th 2024

Lurbinectedin demonstrated greater activity and a superior safety profile vs topotecan in a subset of small cell lung cancer.

RATIONALE-315 Data Support Perioperative Tislelizumab Plus Chemo in Resectable NSCLC

February 20th 2024

Neoadjuvant tislelizumab plus platinum-based doublet chemotherapy followed by surgery and adjuvant tislelizumab demonstrated efficacy in resectable non–small cell lung cancer.

NALIRIFOX Approval Revitalizes Pancreatic Cancer Management

February 19th 2024

Zev A. Wainberg, MD, discusses the FDA approval of NALIRIFOX in patients with metastatic pancreatic adenocarcinoma and key data from the NAPOLI 3 trial.

Sammons Spotlights Approaches Under Exploration for HER2+ Breast Cancer and Brain Metastases

February 19th 2024

Sarah Sammons, MD, discusses research efforts in breast cancer focused on HER2-directed therapeutic approaches with central nervous system activity.

Cathy Wu, MD, Wins Prestigious Sjöberg Prize for Cancer Vaccine Research

February 19th 2024

Catherine J. Wu, MD, of Dana-Farber Cancer Institute, has been awarded the Sjöberg Prize today for her pioneering research in the field of personalized vaccines to treat cancer.

UV1 Receives Orphan Drug Designation From EMA in Mesothelioma

February 19th 2024

The European Medicines Agency has granted orphan drug designation to UV1 in patients with mesothelioma.

FDA Accepts BLA for Datopotamab Deruxtecan in Pretreated Advanced Nonsquamous NSCLC

February 19th 2024

A BLA seeking the approval of datopotamab deruxtecan in pretreated nonsquamous non–small cell lung cancer is under review by the FDA.

Maintenance Osimertinib Demonstrates PFS Benefit in Stage III EGFR-Mutant NSCLC

February 19th 2024

Following chemoradiation, maintenance osimertinib improved PFS vs placebo in patients with stage III EGFR-mutant non–small cell lung cancer.

Patient Toxicity and QOL Concerns Must Be Considered in Breast Cancer Treatment Decision-Making

February 19th 2024

Jane L. Meisel, MD, discusses the importance of prioritizing patients’ toxicity concerns and quality of life in the management of breast cancer.

Reflex Molecular Testing May Enhance Targeted Therapy Benefit in Early-Stage Lung Cancer

February 19th 2024

Jobelle Baldonado, MD, highlights the emergence of targeted therapies and the need for reflex-ordered molecular testing in early-stage lung cancer.

Bispecific Antibodies and Noncovalent BTK Inhibitors Expand Horizons in DLBCL and MCL

February 18th 2024

Catherine C. Coombs, MD, spotlights the use of bispecific antibodies in diffuse large B-cell lymphoma and pirtobrutinib in mantle cell lymphoma.